Thank you for visiting the Regenexx online Media Room. We are committed to providing reliable, accurate and interesting news and information. If you don’t find what you need, contact us for information, ideas, resources, artwork, interviews or just answers to questions about Regenexx.
For press inquiries, please contact:
Note to Reporters: The Regenexx procedures currently being offered in the US are 1271.15(b) compliant (same surgical procedure) and not considered a 351 drug by FDA. The only Regenexx procedure considered a drug by FDA was the Regenexx-C procedure, which has not been performed in the U.S. since 2010. For more information on the medical practice and it’s mission, see here…
How We Educate Our Patients and the Public
We are leaders in stem cell research for orthopedics and we believe in following all of our patients in a treatment Registry and publishing the results of our therapies: the good results as well as the treatment failures. Here are some examples of easy to read patient infographics that provide these outcome details on many treated patients:
For our research articles published in medical research journals – see this link